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ABSTRACT Phenotypic drug susceptibility testing (DST) for the two ﬁrst-line tu-
berculosis drugs ethambutol and pyrazinamide is known to yield unreliable and
inaccurate results. In this prospective study, we propose a diagnostic algorithm com-
bining phenotypic DST with Sanger sequencing to inform clinical decision-making
for drug-resistant Mycobacterium tuberculosis complex isolates. Sequencing re-
sults were validated using whole-genome sequencing (WGS) of the isolates.
Resistance-conferring mutations obtained by pncA sequencing correlated well
with phenotypic DST results for pyrazinamide. Phenotypic resistance to ethambu-
tol was only partly explained by mutations in the embB 306 codon. Additional
resistance-conferring mutations were found in the embB gene at codons 354,
406, and 497. In several isolates that tested ethambutol susceptibility by pheno-
typic DST, well-known resistance-conferring embB mutations were determined.
Thus, targeted Sanger sequencing beyond the embB 306 codon or WGS together
with phenotypic DST should be employed to ensure reliable ethambutol drug
susceptibility testing, as a basis for the rational design of multidrug-resistant tu-
berculosis regimens with or without ethambutol.
KEYWORDS Mycobacterium tuberculosis, ethambutol, pyrazinamide
Isoniazid (INH), rifampin (RMP), ethambutol (EMB), and pyrazinamide (PZA) are ﬁrst-line drugs used to treat tuberculosis (TB) caused by the fully susceptible Mycobacte-
rium tuberculosis complex (MTBC) (1). In contrast, multidrug-resistant TB (MDR-TB)
caused by MTBC resistant to both RMP and INH requires prolonged treatment with less
efﬁcacious and more toxic second-line drugs. Drug susceptibility testing (DST) is crucial
to detect resistance, as it informs the choice of effective treatment. While phenotypic
DST (pDST) provides reliable and reproducible results for INH and RMP, it yields less
accurate results for EMB and PZA (2). Potential explanations include an inaccurate
current critical concentration splitting the upper end of the wild-type distribution as
well as methodological variations within diagnostic laboratories (3).
In the context of MDR-TB, EMB and PZA are recommended as “add-on agents”
regardless of pDST results (4). Side effects caused by PZA and EMB, such as nausea,
vomiting, hepatoxicity, and optic neuropathy, often accrete the multiple side effects
caused by second-line drugs (5, 6). If reliable and reproducible DST for EMB and PZA
was available, unnecessary exposure and harmful side effects could be avoided. With
PZA being an integral part of the World Health Organization (WHO) recommended
short-course MDR regimen, the reliable detection of PZA resistance is important for
countries considering a roll-out of this regimen (4).
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Molecular-based methods detecting resistance-conferring mutations proffer alter-
natives to pDST for select drugs. EMB targets the mycobacterial cell wall by inhibiting
the arabinosyl transferases encoded by the embCAB operon, an 10-kb region com-
prising the three adjacent genes embC, embA, and embB (7). Its effect is mainly exerted
upon the polymerization steps in the biosynthesis of the arabinan component of cell
wall arabinogalactan (8). The pncA-encoded nicotinamidase/pyrazinamidase converts
the prodrug PZA to pyrazinoic acid, which disrupts membrane permeability and
transport. In accordance with these mechanisms, resistance to EMB and PZA are mainly
associated with mutations in the embCAB operon, notably codon 306 of embB, and the
pncA gene (9–12).
The present study aimed to investigate an algorithm combining phenotypic and
genotypic (pncA and embB306, Sanger sequencing) approaches to determine PZA and
EMB susceptibility in RMP-resistant TB isolates for routine use in a laboratory.
RESULTS
A total of 85 unrelated clinical isolates, including 7 RMP-monoresistant and 78 MDR
isolates were included. These isolates comprised all four main lineages of M. tubercu-
losis. A total of 43 isolates belonged to lineage 2 “Beijing” (50.6%), 10 to lineage 3
“Delhi-CAS” (11.8%), 2 to lineage 1 “East-African-Indian” (2.4%), and 30 to lineage 4
“Euro-American” (35.3%) (see Fig. S1 in the supplemental material). For a detailed list of
all detected mutations known to be implicated in EMB and PZA resistance as well as the
excluded phylogenetic single nucleotide polymorphisms (SNPs), see Table S1 in the
supplemental material.
Sequencing and phenotypic drug susceptibility. pDST classiﬁed 52 isolates
(61.2%) as PZA resistant. There was 100% concordance between pDST and pncA
sequencing results for 49 PZA-resistant and 33 PZA-susceptible isolates. No PCR results
could be obtained for three resistant isolates. Next-generation sequencing (NGS)
revealed large pncA deletions for two isolates and a pncA T47A mutation for one of
these isolates. A total of 28 different mutations, including one double mutation, were
identiﬁed in the pncA gene. pncA D8G, L4S, and T76P represented the most common
variants (Table S1).
For EMB, 42 (49.4%) isolates tested resistant and 43 (50.6%) susceptible by pDST.
Overall, 60 of the 85 isolates (70.6%) showed concordance between pDST and embB306
sequencing.
Ethambutol-resistant isolates. In less than two-thirds of the 42 EMB-resistant
isolates (24 of 42, 57.14%), phenotypic resistance was conﬁrmed by identifying a
mutation of the embB codon 306 by Sanger sequencing. The remaining 18 isolates were
phenotypically resistant to EMB without evidence of embB306 mutations. We repeated
pDST for isolates with discordant results. Of 18 phenotypically resistant isolates with
embB306 wild type, one isolate tested susceptible on repeat testing. For 16 of the
remaining 17 strains, NGS analysis revealed nonsynonymous, nonphylogenetic muta-
tions in the embCAB operon up- or downstream from the embB306 codon. The
mutation embB Q497R was present in 7 isolates (once in combination with embB
A453A), and embB G406A was found in 5 isolates (once in combination with embB
D1024N). The following SNPs were identiﬁed in only one isolate each: embB S297A
together with embB D1024N, embB D354A with embB D1024N, and embB Q497K. The
mutations embBY319C and embB S297A were present only in pDST-resistant strains.
Phenotypic resistance to EMB occurred at a signiﬁcantly higher frequency in isolates
that carried mutations at embB codon 306 or 497 (chi-square, P  0.0001).
Ethambutol-susceptible isolates. In total, 43 out of 85 isolates (50.6%) tested
phenotypically susceptible. Among these isolates, 7 (16.3%) displayed a codon 306
(M306I) mutation in the embB gene, while the majority were found to be embB306 wild
type (36 out of 43 susceptible isolates [83.7%]). Of these 7 phenotypically susceptible
isolates with an embB306 mutation, 2 isolates tested resistant in a repeated pDST. Of
the remaining 5 phenotypically susceptible isolates with an embB306 mutation, 4
displayed elevated MICs (Table 1). Aside from variants in the embB306 codon, 18
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susceptible isolates had at least one mutation within embCAB. The mutations
embBD354A, embBG406A, and embBQ497K occurred in both pDST-resistant and
-susceptible isolates (Table 1; Fig. 1). Increased MICs were detected in 4 of the 5
susceptible isolates with these mutations. One isolate with an embBD354A and an
additional embBD1024N mutation was tested resistant when repeated. Of the remain-
ing 31 susceptible isolates, with and without the embCAB mutation, 4 were tested
resistant when repeated and 3 had a double mutation in embB (2 times Y334H embA
-12c/T and once embB D328G  embB L74R).
No embR mutation was detected in our data set, while variants in ubiA and aftA were
each found in three cases representing both susceptible and resistant isolates. The two
TABLE 1 embCAB mutations and their corresponding MICs in the selected clinical isolates
pDST
Mutation(s) Susceptible (n  43) (MICs, g/mla) Resistant (n  42)
embA -12c/t 2 (2.5, 3.75)
embA -11c/a 1 (2.5)
embA P838L 1 (1.25)
embB N296H 1 (3.75)
embB S297A  embB D1024N 1
embB M306I 6 (3.75 [n  3], 5 [n  1], 5b [n  2]) 3
embB M306I  embB N296H 1
embB M306I  embA -16c/a 1
embB M306V 1 (2.5) 17
embB M306V  Q497P 1
embB M306V  embA -11c/t 1
embB Y319C 1
embB D328G  embB L74R 1 (5b)
embB Y334H  embA -12c/t 2 (5b, 5b)
embB D354A 1 (5)
embB D354A  embB D1024N 1 (5b) 1
embB T393A 1 (1.25)
embB G406A 1 (5) 4
embB G406A  embB D1024N 1
embB G406D 2 (1.25, 3.75)
embB Q497K 2 (5, 5) 1
embB Q497R 4
embB Q497R  embB Q453A 1
embB Q497R  embC A387V 1
embB Q497R  embA -8c/a 1
embB D1024N 1 (3.75)
embC P707L 1 (2.5)
No mutation 18 (c) 2d
aMICs were tested for susceptible strains only.
bTested resistant when repeated.
c1.25 (n  11), 2.5 (n  6), 5 (n  1) (gspI -240 c/T and Rv3785 c/G at position 4,243,217).
dOne was tested susceptible, when repeated (MIC, 1.25).
FIG 1 Distribution of mutations across the embB codons. Frequencies of mutations at their respective
codon positions are shown. The region covered by the PCR primers currently used and the validated PCR
primers suggested to be used (Table S2) are indicated by black brackets.
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EMB-resistant isolates with a variant in ubiA and one EMB-resistant isolate with a mutation
in aftA also harbored mutations in the embCAB operon. All mutations found in EMB-
resistant and -susceptible isolates within the embCAB operon and in other candidate genes
and the MICs of EMB-susceptible strains are listed in Table S1 and Table 1.
DISCUSSION
This study showed 100% concordance between pDST and pncA Sanger sequencing
for PZA. However, our study afﬁrms that pDST and embB306 sequencing alone is not
sufﬁcient for a reliable determination of EMB resistance (13). Concordance with phe-
notypic resistance was high for some mutations identiﬁed within the embCAB operon,
notably embB M306V and embBQ497R. Additional mutations that were present in both
phenotypically susceptible and resistant isolates in our collection and were associated
with elevated MICs comprise embBQ497K, embBD354A, and embBG406A. This is in
agreement with previously published MIC data showing an association between these
codons and high MICs (9, 14–16). The fact that some of these isolates were initially
classiﬁed as susceptible by pDST is explained by isolate MICs close to the EMB critical
concentration. Our data suggest that an isolate should be regarded as EMB resistant if
any of these mutations are present and an elevated MIC is observed, regardless of the
initial pDST result. Yet, because of the relatively small sample size, no conclusions can
be drawn for other mutations detected in only one or two isolates.
Earlier work suggests that ubiA (Rv3806c) and notably nonsynonymous mutations in
codons 237 and 240 may confer EMB resistance (17). We found three ubiA mutations in
our data set (V55G and two times E149D) in both phenotypically resistant and suscep-
tible isolates. aftA, another enzyme-encoding gene implicated in cell wall synthesis has
also been found to be associated with EMB resistance (18). Our data set revealed
mutations at codon 575 in a susceptible isolate and mutation T611M in a resistant and
susceptible isolate.
pDST in combination with Sanger sequencing of codon 306 in embB correctly
identiﬁed 57.1% (24/42) of EMB-resistant isolates. An additional 16 isolates would have
been detected as EMB resistant if the region covered by Sanger sequencing was
widened to include codons embB297 and embB497, as previously proposed (13, 19, 20).
The sensitivity to predict phenotypic EMB resistance of the embB codon 306 mutations
was 0.57 (speciﬁcity 0.83) which could be increased to 0.9 (speciﬁcity 0.67) when
including embB codons 306, 354, 406, and 497. With all embCAB mutations identiﬁed
among our study isolates, the sensitivity to predict EMB resistance was 0.95 (speciﬁcity
0.42). Primers for an extended PCR spanning these codons have been validated as part
of this study (see Table S2 in the supplemental material). No PCR product could be
obtained for three pDST-resistant isolates. The phenotypic resistance can be explained
by larger deletions in two isolates and a T47A mutation in one isolate. The mutation
T47A has been described to lead to increased MICs close to the resistance breakpoints
(21).
In contrast to previous publications, we report 100% concordance between molec-
ular and phenotypic PZA DST (22). NGS conﬁrmed resistant pDST results in three
additional isolates with noninterpretable Sanger sequencing results. Two of these
isolates had large deletions in the pncA gene. A recent study involving six national
reference laboratories investigating 1,142 MDR strains showed that 10% of isolates with
pncA mutations tested phenotypically susceptible. The majority of pncA variants (85%)
in this study were high-conﬁdence mutations known to be associated with PZA
resistance (11). In a comprehensive mutational screening approach, the PZA-resistance
phenotype of 977 pncA nonsynonymous SNPs was assessed. One-third of the mutations
(n  301) were resistance conferring while another one-third (n  310) were not
associated with phenotypic resistance (23). Of the 28 different pncA mutations identi-
ﬁed in our study, 18 belonged to the resistance-conferring group as per Yadon et al.
(23); none were in the group not associated with resistance.
Recommendation for patient management. One method alone, i.e., pDST, Sanger
sequencing around codon 306 of embB, or NGS, is insufﬁcient to reliably detect EMB
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resistance. Thus, we propose a diagnostic algorithm using phenotypic and genotypic
methods in parallel for all clinical isolates with RMP resistance detected by rapid
molecular (GeneXpert or line probe assays) or phenotypic tests (Fig. 2). If NGS is not
available or only available as a research tool, Sanger sequencing between codon 297
and 497 of embB should be considered (see Table S2 for a validated primer sequence
spanning these embB codons). Interpretation of DST results is straightforward if phe-
notypic and genotypic test results are in agreement. Discordances between phenotypic
and genotypic results may need to be further investigated. However, isolates with
mutations in the embB codons 306, 354, 406, and 497 should be assumed EMB resistant
regardless of the phenotypic DST result (9, 14–16). MICs should be determined for all
phenotypically susceptible isolates with mutations in the genes/operon aftA, ubiA, and
embCAB to elucidate putative additive effects of linked mutations (e.g., embB S297A
and embB D1024N) and the relevance of debatable mutations (e.g., embB Y319C and
N296H) on the EMB-resistance level. If MIC testing is not feasible, repeated pDST at the
critical concentrations should be performed. For those isolates, the microbiologist or
biomedical scientist should relay the uncertainty about the effectiveness of EMB to the
clinician who may or may not consider EMB as an add-on agent.
Implementation of the proposed algorithm is likely to be feasible and relevant in
most low TB incidence, high-resource settings where pDST is routinely performed and
access to NGS is widely available. The majority of MDR-TB cases in Western European
countries are diagnosed among migrants from high TB and/or MDR-TB burden coun-
tries. In Germany, a high proportion of MDR-TB cases are from former Soviet Union and
Eastern Europe countries (24). While the prevalence of EMB resistance among MDR-TB
cases is not systematically reported, the studies reporting EMB resistance show a
consistently high prevalence of 50% (25, 26).
The feasibility of implementing this algorithm in high MDR-TB burden middle or
low-income settings depends on the availability of phenotypic DST and sequencing.
This, in turn, requires technical skills and expertise, infrastructure, appropriate biosafety
measures, and bioinformatics. Over the past years the capacity to perform phenotypic
FIG 2 Algorithm proposed for ethambutol resistance determination in a mycobacterial laboratory in a
low incidence-setting.
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DSTs has greatly increased in many middle or low-income settings. There is great
interest and enthusiasm to rolling out sequencing in low-resource settings, but wide
implementation has not yet happened (27; https://unitaid.org/call-for-proposal/seeking
-projects-to-ﬁght-tuberculosis-and-its-drug-resistant-strains/#en). With sequencing be-
coming more widely available, algorithms such as the one proposed in this study will
be implemented in high MDR-TB burden settings, where they are most needed.
Conclusions. At present, pDST for PZA and EMB cannot be replaced by any
commercially available molecular diagnostic. The one line-probe assay aimed at de-
tecting EMB resistance covers a limited range of resistance-conferring mutations and
does not differentiate between resistance-conferring or silent variants. Thus, Sanger
sequencing or NGS together with pDST should be employed to ensure reliable EMB DST
results, enabling clinicians to decide whether to include EMB as part of an MDR-TB
regimen.
MATERIALS AND METHODS
M. tuberculosis isolates. We included all RMP-resistant clinical isolates referred to the German
National Reference Laboratory for Mycobacteria, Borstel (NRL), between January 2016 and March 2017.
Phenotypic and Sanger-based drug susceptibility testing. pncA and embB306 Sanger sequencing
and pDST for ﬁrst and second-line drugs were done in parallel as part of the diagnostic service. pDST was
performed using the MGIT960 system according to the manufacturer’s instructions (Becton, Dickinson,
Sparks, MD). Processing of isolates and DNA extraction were performed as previously described (28).
MGIT tubes were prepared with 0.8 ml MGIT960 SIRE supplement and, with exception of the drug-free
growth control tubes, 0.1 ml drug solution. The following drug concentrations were tested: PZA at 100
and EMB at 5.0 g/ml. Bacterial suspensions of 0.5 ml were added to the test tubes and the growth-
control tubes.
For molecular DST, pncA and embB306 sequencing were performed as previously described (9, 29).
MIC testing for ethambutol. For EMB MIC determination, pDST-susceptible strains were subse-
quently tested at 5.0, 3.75, 2.5, and 1.25 g/ml. The provided drug of the Bactec MGIT 960 SIRE kit was
reconstituted into sterile distilled/deionized water as described in the package insert. For the test
concentrations 3.75, 2.5, and 1.25 l/ml, the stock solution was diluted 3:1, 1:1, and 1:3 with sterile
distilled/deionized water before 100 l were added to the respective MGIT tubes. The interpretation was
done with the EpiCenter TBeXiST software according to Springer et al. (30).
Next-generation sequencing and phylogenomic analyses. All isolates underwent next-generation
sequencing (NGS) to conﬁrm mutations and investigate relatedness of isolates. From extracted genomic
DNA, sequencing libraries were constructed using the Nextera XT kit and run on the NextSeq (2  150
bp) sequencing platform (Illumina, San Diego, CA, USA). Reads were mapped to the reference genome
M. tuberculosis H37Rv (GenBank accession number NC_000962.3) with the alignment program BWA.
Reads were reﬁned using the Genome Analysis Toolkit (GATK) and SAMtools. For variant calling in the
mapped reads, we used SAMtools and custom perl scripts with minimum thresholds of four reads in both
forward and reverse orientation and 75% allele frequency. Variants in repetitive regions or genes were
masked. Single nucleotide polymorphism (SNP) positions with a clear base call in all isolates were
concatenated to a sequence alignment. A maximum likelihood tree was inferred using FastTree with
1,000 resamples (31). The consensus tree was midpoint rooted in FigTree, and nodes were arranged in
increasing order.
Accession number(s). The sequence read sets were deposited in the European Nucleotide Archive
under the BioProject accession number PRJEB27354.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/AAC
.01798-18.
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